KLP Kapitalforvaltning AS Has $1.32 Million Stock Position in Halozyme Therapeutics, Inc. $HALO

KLP Kapitalforvaltning AS reduced its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 2.3% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 25,400 shares of the biopharmaceutical company’s stock after selling 600 shares during the quarter. KLP Kapitalforvaltning AS’s holdings in Halozyme Therapeutics were worth $1,321,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Isthmus Partners LLC lifted its stake in shares of Halozyme Therapeutics by 2.5% in the first quarter. Isthmus Partners LLC now owns 6,875 shares of the biopharmaceutical company’s stock worth $439,000 after acquiring an additional 169 shares during the period. OneDigital Investment Advisors LLC increased its holdings in Halozyme Therapeutics by 1.7% in the first quarter. OneDigital Investment Advisors LLC now owns 10,176 shares of the biopharmaceutical company’s stock worth $649,000 after purchasing an additional 175 shares in the last quarter. Park Place Capital Corp increased its holdings in Halozyme Therapeutics by 20.1% in the first quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company’s stock worth $69,000 after purchasing an additional 182 shares in the last quarter. Xponance Inc. increased its holdings in Halozyme Therapeutics by 1.1% in the first quarter. Xponance Inc. now owns 18,652 shares of the biopharmaceutical company’s stock worth $1,190,000 after purchasing an additional 198 shares in the last quarter. Finally, Bessemer Group Inc. increased its holdings in Halozyme Therapeutics by 62.9% in the first quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 207 shares in the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction on Friday, October 3rd. The stock was sold at an average price of $69.03, for a total transaction of $1,380,600.00. Following the completion of the sale, the chief executive officer owned 733,719 shares in the company, valued at approximately $50,648,622.57. This represents a 2.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Nicole Labrosse sold 2,227 shares of the company’s stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $77.95, for a total value of $173,594.65. Following the sale, the chief financial officer owned 22,079 shares of the company’s stock, valued at $1,721,058.05. This trade represents a 9.16% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 108,227 shares of company stock worth $7,779,595. 2.90% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on HALO. Weiss Ratings upgraded Halozyme Therapeutics from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, October 8th. The Goldman Sachs Group began coverage on Halozyme Therapeutics in a report on Thursday, July 10th. They issued a “neutral” rating and a $55.00 target price for the company. JPMorgan Chase & Co. lifted their target price on Halozyme Therapeutics from $60.00 to $63.00 and gave the stock a “neutral” rating in a report on Thursday, August 7th. Wall Street Zen downgraded Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, September 5th. Finally, Benchmark upped their target price on Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a research report on Wednesday, September 24th. Six investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $70.44.

Halozyme Therapeutics Price Performance

Shares of NASDAQ:HALO opened at $65.33 on Tuesday. The company has a quick ratio of 7.01, a current ratio of 8.36 and a debt-to-equity ratio of 4.54. Halozyme Therapeutics, Inc. has a twelve month low of $42.01 and a twelve month high of $79.50. The stock’s 50 day moving average is $71.19 and its 200-day moving average is $61.98. The firm has a market capitalization of $7.64 billion, a price-to-earnings ratio of 14.95, a PEG ratio of 0.34 and a beta of 1.16.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share for the quarter, topping analysts’ consensus estimates of $1.23 by $0.31. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The company had revenue of $325.72 million for the quarter, compared to analyst estimates of $282.66 million. During the same period in the prior year, the firm earned $0.91 earnings per share. Halozyme Therapeutics’s revenue for the quarter was up 40.8% on a year-over-year basis. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. Sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.